Drugs / SL-1002
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials · 1 met primary | ||||||
| Phase 2 | NCT05470608 | Jun 2022 → Jan 2024 | osteoarthritis, knee | Saol Therapeutics Inc | Unknown | No outcome recorded |
| Phase 2 | NCT05311215 | Apr 2022 → Sep 2023 | — | Saol Therapeutics Inc | Unknown | Met primary |
| Phase 31 trial | ||||||
| Phase 3 | NCT07226258 | Nov 2025 → Nov 2026 expected | osteoarthritis, knee | Saol Therapeutics Inc | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2024-10-30 | Saol Therapeutics Inc | Results Saol Therapeutics Announces Positive Topline Results from the SL-1002 RAISE Limb Spasticity Trial saolrx.com ↗
SL-1002 demonstrated a favorable safety profile in adult patients with limb spasticity, achieving the primary safety endpoint of this first-in-human study. |
| 2023-04-12 | Saol Therapeutics Inc | Results Saol Therapeutics Announces Advancement into the Efficacy Expansion Cohort of the Phase II COMPASS Trial Evaluating the Safety and Efficacy Profile of SL-1002 for Treatment of Knee Pain Associated with Osteoarthritis saolrx.com ↗
The third cohort of the COMPASS trial confirmed the highest planned dose target for the study is well tolerated. |
All press releases naming this drug 5 releases
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SL-1002 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05470608 ↗ |